The wheels are turning for Takeda’s huge acquisition of Shire, assuming the European Commission’s approval on antitrust concerns, and the approval of the respective companies’ stakeholders. The $62.4b deal is the biggest overseas M&A deal in Japanese history, and brings with it speculation of future divestments by Takeda.
Author: Ian Haydock
Published: 12 November 2018
Number of pages:4
Details for the $62.4b acquisition of Shire PLC by Takeda Pharmaceutical Co. Ltd. have begun to crystalize as critical dates for European Commission and shareholder approval for the historic event are set. Japan’s biggest overseas M&A acquisition ever, the Shire takeover brings with it the specter of possible future divestments as a means of mitigating company debt. Find out more about the mega-deal, details about the funding structure of this transaction, and possible future repercussions of the merger in this illuminating article from Scrip.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.